Shareholders

First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions Completes First Import Shipment in China, with the First Global Prescription Issued in Beijing on the Same Day

Asieris publishes Annual Report and shares Market approval of Richard Wolf System blue equipment in China

Blue Light Cystoscopy demonstrates cost neutrality through reduced recurrence in real-world BRAVO study

Update on KARL STORZ’s Citizen Petition

Asieris: Cevira Endorsed with Level 1A Evidence in Expert Consensus